Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $1,132,000.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $11.32, for a total transaction of $1,132,000.00. Following the completion of the transaction, the chief operating officer now owns 606,525 shares in the company, valued at $6,865,863. This trade represents a 14.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Price Performance

NASDAQ ROIV opened at $12.53 on Monday. The business’s fifty day moving average is $11.69 and its 200-day moving average is $11.33. The stock has a market capitalization of $9.27 billion, a price-to-earnings ratio of 2.22 and a beta of 1.24. Roivant Sciences Ltd. has a one year low of $8.61 and a one year high of $13.06.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. American International Group Inc. increased its stake in shares of Roivant Sciences by 7,589.5% in the first quarter. American International Group Inc. now owns 450,065 shares of the company’s stock worth $4,744,000 after purchasing an additional 444,212 shares in the last quarter. Magnetar Financial LLC bought a new stake in Roivant Sciences during the 1st quarter valued at $1,576,000. Clearbridge Investments LLC lifted its position in shares of Roivant Sciences by 51.3% during the second quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock worth $19,666,000 after acquiring an additional 630,712 shares in the last quarter. Cetera Advisors LLC bought a new position in shares of Roivant Sciences in the first quarter worth $758,000. Finally, Point72 Asset Management L.P. grew its position in shares of Roivant Sciences by 40.1% in the second quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock valued at $6,840,000 after purchasing an additional 185,226 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. Finally, Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research note on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.